This signifies an increase, as the total annual revenue up to the end of September rose to $700,000, compared to $200,000 for the previous year.
The company remains committed to expanding its market presence to drive further sales growth.\nIn a notable development, a patient in Türkiye successfully underwent surgery following treatment with the OncoSil device, highlighting its effectiveness.
\"The successful resection in Türkiye is a breakthrough moment for OncoSil,\" stated Nigel Lange, CEO & Managing Director of OncoSil Medical.
The Spanish market also saw the completion of its 30th patient treatment using the OncoSil™ device.
Twelve sites in Spain are currently operational, with four additional sites ready to commence treatments, illustrating significant market expansion.
In addition to its operational successes, OncoSil has achieved a 50% patient recruitment milestone in both its TRIPP-FXX and PANCOSIL clinical trials, crucial for the continued evaluation of the OncoSil device.\nOncoSil Medical is a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer.
At the time of reporting, OncoSil Medical's share price was $0.0080.","mainEntityOfPage":"https://grafa.com/news/health-oncosil-medical-gains-momentum-with-q1-fy25-progress-298336","headline":"OncoSil Medical gains momentum with Q1 FY25 progress","image":["https://images.grafa.com/grafa/media-health-oncosil-medical-gains-momentum-with-q1-fy25-progress-298336-638659455432089180.jpeg"],"dateModified":"2024-10-31T04:25:43+0000","author":[{"@type":"Person","name":"Heidi Cuthbert","url":"http://grafa.com/author/heidi-cuthbert","sameAs":["https://twitter.com/heidicuthbert","https://www.linkedin.com/in/heidi-cuthbert-13372923/"]}],"publisher":{"@id":"https://grafa.com/#publisher","@type":"Organization","name":"Grafa","url":"https://grafa.com","logo":{"@type":"ImageObject","url":"https://images.grafa.com/publishers/grafa-100.jpg","width":65,"height":65}}},{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://grafa.com/news/australia/breaking"},{"@type":"ListItem","position":2,"name":"OncoSil Medical gains momentum with Q1 FY25 progress","item":"https://grafa.com/news/health-oncosil-medical-gains-momentum-with-q1-fy25-progress-298336"}]},{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://grafa.com/news/australia/breaking"},{"@type":"ListItem","position":2,"name":"Theme","item":"https://grafa.com/news/theme/oncosil-device"},{"@type":"ListItem","position":3,"name":"OncoSil Medical gains momentum with Q1 FY25 progress","item":"https://grafa.com/news/health-oncosil-medical-gains-momentum-with-q1-fy25-progress-298336"}]},{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://grafa.com/news/australia/breaking"},{"@type":"ListItem","position":2,"name":"Theme","item":"https://grafa.com/news/theme/advanced-pancreatic-cancer"},{"@type":"ListItem","position":3,"name":"OncoSil Medical gains momentum with Q1 FY25 progress","item":"https://grafa.com/news/health-oncosil-medical-gains-momentum-with-q1-fy25-progress-298336"}]},{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://grafa.com/news/australia/breaking"},{"@type":"ListItem","position":2,"name":"Theme","item":"https://grafa.com/news/theme/revenue-growth"},{"@type":"ListItem","position":3,"name":"OncoSil Medical gains momentum with Q1 FY25 progress","item":"https://grafa.com/news/health-oncosil-medical-gains-momentum-with-q1-fy25-progress-298336"}]},{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://grafa.com/news/australia/breaking"},{"@type":"ListItem","position":2,"name":"Theme","item":"https://grafa.com/news/theme/strategic-expansion"},{"@type":"ListItem","position":3,"name":"OncoSil Medical gains momentum with Q1 FY25 progress","item":"https://grafa.com/news/health-oncosil-medical-gains-momentum-with-q1-fy25-progress-298336"}]},{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://grafa.com/news/australia/breaking"},{"@type":"ListItem","position":2,"name":"Theme","item":"https://grafa.com/news/theme/clinical-trial"},{"@type":"ListItem","position":3,"name":"OncoSil Medical gains momentum with Q1 FY25 progress","item":"https://grafa.com/news/health-oncosil-medical-gains-momentum-with-q1-fy25-progress-298336"}]},{"@context":"http://schema.org","@type":"Table","headline":"OncoSil Medical gains momentum with Q1 FY25 progress","about":"News article about OncoSil Medical gains momentum with Q1 FY25 progress"},{"@context":"https://schema.org","@type":"WebSite","url":"https://grafa.com","potentialAction":{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://grafa.com/search?q={search_term_string}"},"query-input":"required name=search_term_string"}}]
OncoSil Medical (ASX:OSL), a medical device company specialising in the treatment of locally advanced pancreatic cancer, recorded a revenue of $166,000 for the first quarter of FY25 ended Sept. 30.
This signifies an increase, as the total annual revenue up to the end of September rose to $700,000, compared to $200,000 for the previous year.
The company remains committed to expanding its market presence to drive further sales growth.
In a notable development, a patient in Türkiye successfully underwent surgery following treatment with the OncoSil device, highlighting its effectiveness.
"The successful resection in Türkiye is a breakthrough moment for OncoSil," stated Nigel Lange, CEO & Managing Director of OncoSil Medical.
The Spanish market also saw the completion of its 30th patient treatment using the OncoSil™ device.
Twelve sites in Spain are currently operational, with four additional sites ready to commence treatments, illustrating significant market expansion.
In addition to its operational successes, OncoSil has achieved a 50% patient recruitment milestone in both its TRIPP-FXX and PANCOSIL clinical trials, crucial for the continued evaluation of the OncoSil device.
OncoSil Medical is a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer.
At the time of reporting, OncoSil Medical's share price was $0.0080.